AMENDMENT NO. 1 TO AMENDED AND RESTATED CAS9‑I LICENSE AGREEMENTCas9-I License Agreement • March 7th, 2017 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amendment No. 1 (the “Amendment”) to that certain Amended and Restated Cas9‑I License Agreement, by and among Editas Medicine, Inc. (the “Company”), President and Fellows of Harvard College (“Harvard”) and the Broad Institute, Inc. (“Broad”), dated December 16, 2016 (the “Agreement”), is made as of the 3rd day of March, 2017 (the “Amendment Effective Date”), by and among the Company, Harvard and Broad. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are given in the Agreement.
